MXPA04003533A - Agentes de intensificacion de afinidad. - Google Patents

Agentes de intensificacion de afinidad.

Info

Publication number
MXPA04003533A
MXPA04003533A MXPA04003533A MXPA04003533A MXPA04003533A MX PA04003533 A MXPA04003533 A MX PA04003533A MX PA04003533 A MXPA04003533 A MX PA04003533A MX PA04003533 A MXPA04003533 A MX PA04003533A MX PA04003533 A MXPA04003533 A MX PA04003533A
Authority
MX
Mexico
Prior art keywords
binding protein
seq
polypeptide
binding
diabody
Prior art date
Application number
MXPA04003533A
Other languages
English (en)
Spanish (es)
Inventor
Rossi Edmund
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Publication of MXPA04003533A publication Critical patent/MXPA04003533A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
MXPA04003533A 2001-10-15 2002-10-15 Agentes de intensificacion de afinidad. MXPA04003533A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32883501P 2001-10-15 2001-10-15
US34188101P 2001-12-21 2001-12-21
PCT/US2002/032717 WO2003033653A2 (en) 2001-10-15 2002-10-15 Affinity enhancement agents

Publications (1)

Publication Number Publication Date
MXPA04003533A true MXPA04003533A (es) 2005-06-20

Family

ID=26986533

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04003533A MXPA04003533A (es) 2001-10-15 2002-10-15 Agentes de intensificacion de afinidad.

Country Status (13)

Country Link
US (1) US20030113333A1 (enExample)
EP (1) EP1444267B1 (enExample)
JP (1) JP4443923B2 (enExample)
KR (1) KR101027889B1 (enExample)
CN (1) CN1604910A (enExample)
AU (1) AU2002335808B2 (enExample)
BR (1) BR0213284A (enExample)
CA (1) CA2463616C (enExample)
IL (1) IL161417A0 (enExample)
MX (1) MXPA04003533A (enExample)
PL (1) PL374426A1 (enExample)
RU (1) RU2004114878A (enExample)
WO (1) WO2003033653A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US6346454B1 (en) * 1999-01-12 2002-02-12 Agere Systems Guardian Corp. Method of making dual damascene interconnect structure and metal electrode capacitor
US20040018557A1 (en) * 2002-03-01 2004-01-29 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
US20050003403A1 (en) * 2003-04-22 2005-01-06 Rossi Edmund A. Polyvalent protein complex
CA2531118C (en) * 2003-07-01 2013-01-08 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
CN101171034B (zh) 2005-03-03 2014-06-18 免疫医疗公司 人源化l243抗体
AU2009239491B2 (en) 2008-04-21 2014-07-17 Lawrence Livermore National Security, Llc Selective high-affinity polydentate ligands and methods of making such
US9050375B2 (en) * 2009-07-06 2015-06-09 Hoffmann-La Roche, Inc. Bi-specific digoxigenin binding antibodies
US9264453B2 (en) 2013-11-08 2016-02-16 At&T Mobility Ii Llc Front end processor for short message service centers
AU2024233139A1 (en) * 2023-03-03 2025-08-28 Oncoone Research & Development Gmbh Improved bispecific anti-tumor antigen/anti-hsg antibodies for pre-targeting of hyperproliferative disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
FR2604092B1 (fr) * 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6027725A (en) * 1991-11-25 2000-02-22 Enzon, Inc. Multivalent antigen-binding proteins
US6096289A (en) * 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
CA2145278C (en) * 1992-09-25 2009-03-10 Commonwealth Scientific And Industrial Research Organisation Target binding polypeptide
ATE199392T1 (de) * 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US5989830A (en) * 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
US6254868B1 (en) * 1996-03-20 2001-07-03 Immunomedics, Inc. Glycosylated humanized B-cell specific antibodies
WO1997038102A1 (en) * 1996-04-04 1997-10-16 Unilever Plc Multivalent and multispecific antigen-binding protein
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US7074405B1 (en) * 1998-06-22 2006-07-11 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
PL372144A1 (en) * 2001-12-26 2005-07-11 Immunomedics, Inc. Methods of generating multispecific, multivalent agents from v sb h /sb and v sb l /sb domains

Also Published As

Publication number Publication date
CA2463616C (en) 2011-07-12
EP1444267A4 (en) 2009-12-02
RU2004114878A (ru) 2005-04-20
WO2003033653A3 (en) 2003-11-13
IL161417A0 (en) 2004-09-27
JP2005518344A (ja) 2005-06-23
CN1604910A (zh) 2005-04-06
KR101027889B1 (ko) 2011-04-07
JP4443923B2 (ja) 2010-03-31
EP1444267B1 (en) 2016-08-10
KR20050036873A (ko) 2005-04-20
EP1444267A2 (en) 2004-08-11
BR0213284A (pt) 2006-05-23
WO2003033653B1 (en) 2004-02-12
CA2463616A1 (en) 2003-04-24
PL374426A1 (en) 2005-10-17
AU2002335808B2 (en) 2009-08-27
US20030113333A1 (en) 2003-06-19
WO2003033653A2 (en) 2003-04-24

Similar Documents

Publication Publication Date Title
CN110627906A (zh) 抗pd-l1/4-1bb双特异性抗体及其用途
US20230001004A1 (en) Cys80 conjugated immunoglobulins
US20240368264A1 (en) Anti-TSLP nanobodies and their applications
JP7691720B2 (ja) 抗ヒトｃｄ７３抗体およびその適用
US20230167200A1 (en) Platform for constructing multispecific antibody
JP2012511033A (ja) 多価化合物の可逆阻害用マスキングリガンド
CN109485726B (zh) 放射性标记抗纳米抗体在癌症的预后、诊断中的应用
JP2021508314A (ja) 血清中のタンパク質の半減期を増加させるための組成物及び方法
CN114685666B (zh) 抗间皮素纳米抗体及其应用
EP1444267B1 (en) Affinity enhancement agents
CN117279950A (zh) 一种靶向il-18bp的抗体及其应用
AU2002335808A1 (en) Affinity enhancement agents
CN111247249B (zh) Dna、多肽、抗间皮素抗体、肿瘤成像剂和复合体
CN114380907B (zh) 靶向cmtm6的纳米抗体及其制备方法和应用
CN109879966A (zh) 基于鼠源cd19抗体的人源化设计及表达验证
CN114685667A (zh) 间皮素结合分子及其应用
Yang et al. A strategy for high-level expression of a single-chain variable fragment against TNFα by subcloning antibody variable regions from the phage display vector pCANTAB 5E into pBV220
CN115124621B (zh) 靶向pd-l1的纳米抗体及其制备方法和应用
CN111018984B (zh) 抗ck8单克隆抗体及其应用
CN119912562B (zh) 抗β-catenin的纳米抗体及制备方法和应用
JP2015062367A (ja) Ｒｏｂｏ１タンパク質に対するダイアボディ型二重特異性抗体
JP2023516380A (ja) プロテアーゼプロセシングした分子
EP2953975B1 (en) Immuno imaging agent for use with antibody-drug conjugate therapy
HK40083794A (en) Platform for constructing multispecific antibody
CN121949555A (zh) 抗Trop2纳米抗体及其产品和应用

Legal Events

Date Code Title Description
FA Abandonment or withdrawal